Cargando…

Safety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patients

Asthma is a disease of all ages. This assumption has been challenged in the past, because of several cultural and scientific biases. A large body of evidence has accumulated in recent years to confirm that the prevalence of asthma in the most advanced ages is similar to that in younger ages. Asthma...

Descripción completa

Detalles Bibliográficos
Autores principales: Scichilone, Nicola, Battaglia, Salvatore, Benfante, Alida, Bellia, Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794872/
https://www.ncbi.nlm.nih.gov/pubmed/24124355
http://dx.doi.org/10.2147/CIA.S35977
_version_ 1782287280140976128
author Scichilone, Nicola
Battaglia, Salvatore
Benfante, Alida
Bellia, Vincenzo
author_facet Scichilone, Nicola
Battaglia, Salvatore
Benfante, Alida
Bellia, Vincenzo
author_sort Scichilone, Nicola
collection PubMed
description Asthma is a disease of all ages. This assumption has been challenged in the past, because of several cultural and scientific biases. A large body of evidence has accumulated in recent years to confirm that the prevalence of asthma in the most advanced ages is similar to that in younger ages. Asthma in the elderly may show similar functional and clinical characteristics to that occurring in young adults, although the frequent coexistence of comorbid conditions in older patients, together with age-associated changes in the human lung, may lead to more severe forms of the disease. Management of asthma in the elderly follows specific guidelines that apply to all ages, although most behaviors are pure extrapolation of what has been tested in young ages. In fact, age has always represented an exclusion criterion for eligibility to clinical trials. This review focuses specifically on the safety and efficacy of leukotriene modifiers, which represent a valid option in the treatment of allergic asthma, both as an alternative to first-line drugs and as add-on treatment to inhaled corticosteroids. Available studies specifically addressing the role of montelukast in the elderly are scarce; however, leukotriene modifiers have been demonstrated to be safe in this age group, even though cases of acute hepatitis and occurrence of Churg-Strauss syndrome have been described in elderly patients; whether this is associated with age is to be confirmed. Furthermore, leukotriene modifiers provide additional benefit when added to regular maintenance therapy, not differently from young asthmatics. In elderly patients, the simpler route of administration of leukotriene modifiers, compared with the inhaled agents, could represent a more effective strategy in improving the outcomes of asthma therapy, given that unintentional nonadherence with inhalation therapy represents a complex problem that may lead to significant impairment of asthma symptom control.
format Online
Article
Text
id pubmed-3794872
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-37948722013-10-11 Safety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patients Scichilone, Nicola Battaglia, Salvatore Benfante, Alida Bellia, Vincenzo Clin Interv Aging Review Asthma is a disease of all ages. This assumption has been challenged in the past, because of several cultural and scientific biases. A large body of evidence has accumulated in recent years to confirm that the prevalence of asthma in the most advanced ages is similar to that in younger ages. Asthma in the elderly may show similar functional and clinical characteristics to that occurring in young adults, although the frequent coexistence of comorbid conditions in older patients, together with age-associated changes in the human lung, may lead to more severe forms of the disease. Management of asthma in the elderly follows specific guidelines that apply to all ages, although most behaviors are pure extrapolation of what has been tested in young ages. In fact, age has always represented an exclusion criterion for eligibility to clinical trials. This review focuses specifically on the safety and efficacy of leukotriene modifiers, which represent a valid option in the treatment of allergic asthma, both as an alternative to first-line drugs and as add-on treatment to inhaled corticosteroids. Available studies specifically addressing the role of montelukast in the elderly are scarce; however, leukotriene modifiers have been demonstrated to be safe in this age group, even though cases of acute hepatitis and occurrence of Churg-Strauss syndrome have been described in elderly patients; whether this is associated with age is to be confirmed. Furthermore, leukotriene modifiers provide additional benefit when added to regular maintenance therapy, not differently from young asthmatics. In elderly patients, the simpler route of administration of leukotriene modifiers, compared with the inhaled agents, could represent a more effective strategy in improving the outcomes of asthma therapy, given that unintentional nonadherence with inhalation therapy represents a complex problem that may lead to significant impairment of asthma symptom control. Dove Medical Press 2013 2013-10-02 /pmc/articles/PMC3794872/ /pubmed/24124355 http://dx.doi.org/10.2147/CIA.S35977 Text en © 2013 Scichilone et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Scichilone, Nicola
Battaglia, Salvatore
Benfante, Alida
Bellia, Vincenzo
Safety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patients
title Safety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patients
title_full Safety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patients
title_fullStr Safety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patients
title_full_unstemmed Safety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patients
title_short Safety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patients
title_sort safety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patients
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794872/
https://www.ncbi.nlm.nih.gov/pubmed/24124355
http://dx.doi.org/10.2147/CIA.S35977
work_keys_str_mv AT scichilonenicola safetyandefficacyofmontelukastasadjunctivetherapyfortreatmentofasthmainelderlypatients
AT battagliasalvatore safetyandefficacyofmontelukastasadjunctivetherapyfortreatmentofasthmainelderlypatients
AT benfantealida safetyandefficacyofmontelukastasadjunctivetherapyfortreatmentofasthmainelderlypatients
AT belliavincenzo safetyandefficacyofmontelukastasadjunctivetherapyfortreatmentofasthmainelderlypatients